2016
DOI: 10.1021/acs.oprd.5b00404
|View full text |Cite
|
Sign up to set email alerts
|

Process Development and Scale-up of Fully Synthetic Tetracycline TP-2758: A Potent Antibacterial Agent with Excellent Oral Bioavailability

Abstract: Process research and development of the fully synthetic broad spectrum tetracycline TP-2758, with a chiral pyrrolidine side chain at the C-8 position, is described. The process utilizes two key intermediates, 7 and 10, in a convergent approach that allows for manufacturing of sufficient quantities of API to supply preclinical and early clinical development. The pyrrolidine moiety was introduced into the left-hand piece (LHP) 10 with high enantioselectivity using Ellman’s sulfinamide chemistry, and the absolute… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(12 citation statements)
references
References 19 publications
0
12
0
Order By: Relevance
“…This approach produced one clinically approved antibiotic (eravacycline) and two other phase 1 candidates (TP-271 and TP-6076). TP-2758, with a chiral 8-pyrrolidinyl substitution, was discovered while generating a series of novel 7-methoxy-8-heterocyclyl tetracycline analogs ( 48 ). Derivatives of tetracyclines, called glycylcyclines, were developed to combat the rise of tetracycline resistance.…”
Section: Discontinued Candidates With Clinically Validated Targetsmentioning
confidence: 99%
“…This approach produced one clinically approved antibiotic (eravacycline) and two other phase 1 candidates (TP-271 and TP-6076). TP-2758, with a chiral 8-pyrrolidinyl substitution, was discovered while generating a series of novel 7-methoxy-8-heterocyclyl tetracycline analogs ( 48 ). Derivatives of tetracyclines, called glycylcyclines, were developed to combat the rise of tetracycline resistance.…”
Section: Discontinued Candidates With Clinically Validated Targetsmentioning
confidence: 99%
“…From route C, we observed that neither BuLi nor i PrMgClLiCl operated for the carboxylation. However, according to the literature, [31] an exchange Br‐Metal could avoid the formation of undesired side products. The reaction was performed using 1 mmol of the starting material with either BuLi or with i PrMgClLiCl.…”
Section: Resultsmentioning
confidence: 99%
“…Using the organolithium base, no product was observed, whereas with the organomagnesium base, a yield of 41 % of target product was obtained. Attempt to scale‐up (10 mmol) this reaction step, a yield of only 8 % of target product was isolated [31] …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Having developed the racemic arylation/alkenylation reaction, we turned our attention to the discovery of a diastereoselective variant to access enantioenriched products (Table ). Thus, a series of enantioenriched chiral amines, readily prepared using Ellman auxiliary chemistry (i.e., 18 – 24 ), , were condensed with ketoester 9 to access enamines 17 . Subsequent arylation under the conditions depicted in Figure furnished 12 in enantioenriched form.…”
Section: Results and Discussionmentioning
confidence: 99%